Core Points - The Extraordinary General Meeting of Ensurge Micropower ASA was held on 8 August 2025, where all proposals on the agenda were approved by shareholders [1] - The meeting approved the issuance of independent subscription rights to Alexander Munch Thore (13,000,000 rights) and Thomas Ramm (8,000,000 rights), with an exercise price of NOK 1.376 per share [2] - The vesting schedule for the subscription rights includes 40% vesting at the 2026 Annual General Meeting, 30% after 24 months, and the remaining 30% after 36 months, expiring on 8 August 2030 [3] Additional Information - The information is subject to disclosure requirements under the Norwegian Securities Trading Act [4]

Core Points - Galapagos NV has created 925,000 subscription rights under a new plan aimed at senior management compensation [1][2] - The subscription rights have an exercise term of eight years and an exercise price of €25.64, with restrictions on early exercise [2] - The total share capital of Galapagos is €356,444,938.61, with 65,897,071 voting rights currently outstanding [3] Summary by Sections Subscription Rights Plan - The Board of Directors approved "Subscription Right Plan 2025 (A)" for personnel, creating 925,000 subscription rights [1] - Each subscription right allows the holder to subscribe to one new share of Galapagos [2] - The rights cannot be exercised before the third anniversary of issuance [2] Financial Overview - Galapagos' total share capital is €356,444,938.61, with 65,897,071 voting rights [3] - There are 11,866,245 subscription rights from various employee plans, excluding the new rights created [3] - Gilead Therapeutics holds a subscription right to maintain a 29.9% shareholding after exercise [3] Company Profile - Galapagos is a biotechnology company focused on addressing high unmet medical needs through innovative science and technology [4] - The company operates in Europe, the U.S., and Asia, aiming to improve patient outcomes and quality of life [4] - Galapagos is committed to delivering best-in-class medicines and has a decentralized cell therapy manufacturing platform [4]

Core Points - The Nomination Committee was elected at the AGM on 14 May 2024, consisting of Robert N. Keith (Chair), Rune Sundvall, and Christian Schlytter-Henrichsen [1] - Two members of the Nomination Committee resigned, leaving only Robert N. Keith, which is below the minimum required by the Company's Articles of Association [2] - The Chair has been in contact with the Company's management and major shareholders to define the desired profile of Board members [3] Board Composition - The current Board consists of Terje Rogne (Chair), Morten Opstad, and Nina Riibe, all of whom are up for re-election at the upcoming AGM [5][6] - The current Board members are willing to continue for a new two-year term, and the Nomination Committee proposes their re-election [6][7] Board Remuneration - The remuneration for Board members for the period from the 2025 AGM to the 2026 AGM is proposed to be NOK 300,000 per member, payable quarterly [10] - The same level of cash remuneration is proposed for the next term, with the first payment due on 31 August 2025 [10] Subscription Rights - The Nomination Committee proposes grants of incentive subscription rights to Terje Rogne (16,000,000 rights) and Morten Opstad (5,000,000 rights) [11][13] - The vesting schedule for these subscription rights is proposed to be 10% after one year, 20% after two years, and 70% after three years [12][17] Nomination Committee Remuneration - The Chair of the Nomination Committee proposes that no remuneration is paid to the resigned members for their services from the 2024 AGM until their resignations [23] - Robert N. Keith waives his right to a remuneration fee [23] Nomination Committee Election - Robert N. Keith is proposed to be re-elected as Chair of the Nomination Committee, with Andreas Ellingsen and Fredrik Munck as new members for a one-year term [24]